2-氯-6-三氟甲氧基苯并噻唑 | 133840-96-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-氯-6-三氟甲氧基苯并噻唑
• 中文别名: 2-氯-6-三氟甲氧基苯并[D]噻唑；利鲁唑
• 英文名称: 2-chloro-6-(trifluoromethoxy)benzothiazole
• 英文别名: 2-Chloro-6-(trifluoromethoxy)Benzo[d]thiazole；2-chloro-6-(trifluoromethoxy)-1,3-benzothiazole
• CAS: 133840-96-7
• 化学式: C₈H₃ClF₃NOS
• 分子量: 253.632
• InChiKey: PPGSYGPSOLZOOU-UHFFFAOYSA-N

物化性质

• 沸点：
  250.8±35.0 °C(Predicted)
• 密度：
  1.599±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  50.4
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 海关编码：
  2934200090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  储存条件：室温、密封、干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-6-(trifluoromethoxy)benzothiazole
Synonyms: 2-Chloro-6-(trifluoromethoxy)benzo[d]thiazole

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-6-(trifluoromethoxy)benzothiazole
CAS number: 133840-96-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H3ClF3NOS
Molecular weight: 253.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride, sulfur
oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

2-氯-6-三氟甲氧基苯并噻唑是一类非常重要的杂环化合物，主要应用于医药、农业及工业等领域。

合成方法

以利鲁唑为原料，与硫酸肼进行回流反应，将其2-位氨基转化为肼基，从而制得2-肼基-6-三氟甲氧基苯并噻唑；再经氯化亚砜氯代反应，最终制得2-氯-6-三氟甲氧基苯并噻唑。

反应信息

• 作为反应物：
  描述：

  2-氯-6-三氟甲氧基苯并噻唑 在 氢氧化钾 、 盐酸羟胺 作用下， 以 甲醇 、 环己烷 、 乙酸乙酯 为溶剂， 生成 N-羟基利鲁唑
  参考文献：
  名称：

  6-polyfluoroalkoxy-and 6-polyfluoroalkyl-2-aminobenzothiazole derivatives

  摘要：

  式(I)的化合物：##STR1## 其中R是多氟烷氧基或多氟烷基基团，R.sub.1是氢原子，R.sub.2是羟基基团，或者R.sub.1是羟基基团，R.sub.2是氢原子，其盐类，制备所述化合物的方法以及含有它们的药物。

  公开号：

  US05795903A1
• 作为产物：
  描述：

  2-亚肼基-6-(三氟甲氧基)-2,3-二氢苯并[d]噻唑 在 氯化亚砜 作用下， 反应 5.0h， 以85%的产率得到2-氯-6-三氟甲氧基苯并噻唑
  参考文献：
  名称：

  某些新的利鲁唑衍生物的合成，晶体结构和镇痛作用

  摘要：

  合成了九种利鲁唑的N-烷基化衍生物，以获得具有潜在抗伤害感受活性的新化合物。首先将利鲁唑转化为（6-三氟甲氧基-苯并噻唑-2-基）-肼，然后用SOCl 2氯化，得到2-氯-6-三氟甲氧基-苯并噻唑。该中间产物用九种烷基胺处理，分别得到利鲁唑的N-烷基化衍生物。通过元素分析，IR，1 H NMR和13确认化合物的结构1 H NMR。优化了合成路线，并通过重结晶获得了四个新颖的​​晶体。这项研究通过热板实验在小鼠中研究了利鲁唑的某些N-烷基化衍生物的抗伤害感受活性。研究了抗伤害感受活性与4b，4c，4h，4g和利鲁唑剂量之间的关系。与对照组（0 mg / kg）相比，化合物4b和4h的作用显着增加（分别为13.78±2.89 s，12.89±2.94 s）。化合物4c在小鼠停留在热板上的时间显示出极大的显着增加（18.07±3.08 s）。化合物4b，4c，与空白溶剂组相比，4h增加了潜伏时间

  DOI：

  10.1007/s00044-018-2154-4

文献信息

• Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
  申请人：Bayer Pharmaceuticals Corporation

  公开号：US20040224997A1

  公开（公告）日：2004-11-11

  This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases.

  这项发明涉及某些芳基烷基酸化合物、组合物以及治疗或预防肥胖和相关疾病的方法。
• [EN] BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF CXCR3 FUNCTION<br/>[FR] DERIVES HETEROAROMATIQUES BICYCLIQUES EN TANT QUE MODULATEURS DE LA FONCTION CXCR3
  申请人：CELLTECH R&D LTD

  公开号：WO2005003127A1

  公开（公告）日：2005-01-13

  A class of 1-substituted 4-(benzothiazol-2-ylamino) piperidine derivatives and related heterocyclic compounds, being potent and selective modulators of the interaction between CXCR3 and its chemokine ligands, are accordingly of use in the treatment and/or prevention of conditions involving inappropriate T-cell trafficking, including inflammatory, autoimmune and immunoregulatory disorders.

  一类1-取代的4-(苯并噻唑-2-基氨基)哌啶衍生物及相关的杂环化合物，是CXCR3与其趋化因子配体相互作用的有效和选择性调节剂，因此可用于治疗和/或预防涉及不适当T细胞迁移的疾病，包括炎症性、自身免疫和免疫调节性疾病。
• 2-AMINOPYRIDINE KINASE INHIBITORS
  申请人：Steinig Arno G.

  公开号：US20090197862A1

  公开（公告）日：2009-08-06

  2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.

  具有Formula I结构的2-氨基吡啶化合物，以及这些化合物的药用可接受的盐。Formula I的化合物抑制动物（包括人类）中的酪氨酸激酶酶活性，并可用于治疗和/或预防各种疾病和病况。特别地，本文披露的化合物是激酶抑制剂，特别是但不限于KDR、Tie-2、Flt3、FGFR3、Ab1、Aurora A、c-Src、IGF-1R、ALK、c-MET、RON、PAK1、PAK2和TAK1，并可用于治疗增生性疾病，如但不限于癌症。本发明还涉及一种包含Formula I化合物的药物组合物，或其药用可接受的盐，以及药用可接受的载体的药物组合物。本发明还涉及一种通过向患有由蛋白激酶活性介导的病症的患者投与上述药物组合物的治疗方法。
• Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
  申请人：——

  公开号：US20040176430A1

  公开（公告）日：2004-09-09

  The subject invention provides compounds having the structure: 1 wherein R 1 is present or absent, and when present is H, C 1 -C 6 alkyl, C 1 -C 6 alkynyl, —(CH 2 ) y S(CH 2 ) x CH 3 , C 1 -C 6 aminoalkyl, C 1 -C 6 hydroxyalkyl or —(CH 2 ) n C(═O)(C 6 H 4 )(CH 2 )R 2 ; R 2 is H or C 1 -C 4 alkyl; R 3 is H or C 1 -C 4 alkyl; R 4 is present or absent, and when present is H, C 1 -C 6 alkyl, C 1 -C 6 alkynyl, —(CH 2 ) y S(CH 2 ) x CH 3 , C 1 -C 6 aminoalkyl, C 1 -C 6 hydroxyalkyl or —(CH 2 ) n C(═O)(C 6 H 4 )(CH 2 )R 2 ; wherein n is an integer from 1-6; wherein x is 0 or an integer from 1-5 and y is an integer from 1-5, such that x+y<6; at least one of R 1 or R 4 is present; the dashed line represents a bond between one of the nitrogen atoms and the intervening carbon atom; and any compound is charged when both R 1 and R 4 are present, or any specific enantiomer thereof or any pharmaceutically acceptable salt thereof, and a method for treating a neurologic disorder or multiple sclerosis by administering a therapeutically effective amount any of the compounds.

  本发明提供具有以下结构的化合物： 其中R1存在或不存在，当存在时为H、C1-C6烷基、C1-C6炔基、—(CH2)yS(CH2)xCH3、C1-C6氨基烷基、C1-C6羟基烷基或—(CH2)nC(═O)(C6H4)(CH2)R2；R2为H或C1-C4烷基；R3为H或C1-C4烷基；R4存在或不存在，当存在时为H、C1-C6烷基、C1-C6炔基、—(CH2)yS(CH2)xCH3、C1-C6氨基烷基、C1-C6羟基烷基或—(CH2)nC(═O)(C6H4)(CH2)R2；其中n为1-6的整数；其中x为0或1-5的整数，y为1-5的整数，使得x+y<6；R1或R4中至少有一个存在；虚线表示氮原子和介入碳原子之间的键；当R1和R4同时存在时，任何化合物都带电，或其任何特定对映体或其任何药用盐，以及通过给予任何化合物的治疗有效量来治疗神经系统疾病或多发性硬化的方法。
• Process for the preparation of 2-amino-7-nitrobenzo-thiazoles
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05567822A1

  公开（公告）日：1996-10-22

  This invention relates to the process for the preparation of 2-amino 7-nitro benzothiazoles of formula (I) ##STR1## consisting in a) nitrating a derivative of formula (II) ##STR2## and b) reacting the compound of formula (III) ##STR3## so obtained with caustic ammonia.

  这项发明涉及制备2-氨基-7-硝基苯并噻唑的过程，化学式如下：a) 通过对化合物的硝化衍生物进行硝化，化学式如下：b) 用强碱性氨水处理得到的化合物进行反应。